Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer.

Biologics · 2010 · PMC2943196 · PMID 20859451

Europe PMC DOI

hedged sentence

0.1080

closest p · 2.2× alpha

0.1080

boldest claim

The sentences

showed a trendP = 0.108not close (p > 0.1)

After a median follow up duration of nine months, this study showed a trend for improved PFS (HR, 0.86; 97.58% CI: 0.69–1.06, P = 0.108) and OS (HR, 0.86; 97.54% CI: 0.65–1.13; P = 0.219); however, these results were not statistically significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.